alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid in 1 studies
Studies (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Trials (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Recent Studies (post-2010) (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol) | Studies (3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid) | Trials (3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid) | Recent Studies (post-2010) (3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid) |
---|---|---|---|---|---|
90 | 1 | 2 | 755 | 2 | 65 |
Protein | Taxonomy | alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (IC50) | 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (IC50) |
---|---|---|---|
Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 0.1139 | |
Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.1139 | |
Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.1139 | |
Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.1139 | |
Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.1139 | |
Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.1139 | |
Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.1139 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cler, JA; Iyengar, S; Mick, SJ; Rao, TS; Wood, PL | 1 |
1 other study(ies) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid
Article | Year |
---|---|
Inhibition of climbing and mossy fiber, and basket and stellate cell inputs to mouse cerebellar Purkinje cells by novel anti-ischemic agents, ifenprodil and BMY-14802.
Topics: Analysis of Variance; Animals; Cyclic GMP; Harmaline; Male; Methamphetamine; Mice; Mice, Inbred Strains; Neurons; Pentylenetetrazole; Piperazines; Piperidines; Purkinje Cells; Pyrimidines; Radioimmunoassay; Receptors, Amino Acid; Receptors, Cell Surface | 1990 |